CLAIMS

1. (Deleted)

2. (Deleted)

3. (Deleted)

4. (Deleted)

5. (Deleted)

6. (Deleted)

7. (Deleted)

8. (Amended) A compound of the formula (I):



(I)

wherein



is



;

R^1 is $-CH_2-CH=CH-CH_2-CH_2-CH_2-COOR^2$ or $-CH=CH-CH_2-CH_2-CH_2-COOR^2$;

R^2 is hydrogen or alkyl;

m is 0 or 1;

p is 0 or 1, provided that when p = 0, X^1 is not bonded to X^3 via X^4;

X^1 and X^3 each is independently optionally substituted aryl or optionally substituted heteroaryl;

X^2 is a bond, $-CH_2-$, $-CH_2-CH_2-$, -C(=O)-, -O-, -S-, -SO-, $-SO_2-$, -NH-, $-N(CH_3)-$, -C(=N-O-

CH_3)-, -N=N-, -CH=CH-, -(C=O)-NH-, -NH-(C=O)-, -CH_2-NH-, -NH-CH_2-, -CH_2-O-, -O-CH_2-, -CH_2-S-, -S-CH_2-, -CH_2-SO_2-, -SO_2-CH_2-, -SO_2-NH- or -NH-SO_2-;

X^4 is -CH_2-, -CH_2-CH_2-, -C(=O)-, -SO-, -SO_2-, -(C=O)-NH-, -NH-(C=O)-, -CH_2-NH-, -NH-CH_2-, -CH_2-O-, -O-CH_2-, -CH_2-S-, -S-CH_2-, -CH_2-SO_2-, -SO_2-CH_2-, -SO_2-NH- or -NH-SO_2-;

provided that when



is



a compound wherein R^1 is -CH_2-CH=CH-CH_2-CH_2-CH_2-$COOR^2$, R^2 is hydrogen or methyl, m is 0, p is 0, X^1 is phenyl optionally substituted with methoxy, X^2 is a bond, -O-, -CH_2-, -C(=O)-NH-, -S- or -N=N-, and X^3 is phenyl optionally substituted with hydroxy, acetoxy or methoxy, and a compound wherein R^1 is -CH_2-CH=CH-CH_2-CH_2-CH_2-COOH, m is 1, p is 0, X^1 is phenyl, X^2 is -N=N-, and X^3 is phenyl, are excluded, and when



is



R^1 is -CH_2-CH=CH-CH_2-CH_2-CH_2-$COOR^2$, R^2 is hydrogen or methyl, m is 0, and p is 0, a compound wherein X^1 is phenyl optionally substituted with methyl or methoxy, X^2 is a bond, -CH_2-CH_2-, -C(=O)-, -NH-, -O-, -S-, -SO-, -SO_2-, -CH=CH-, -N=N-, -C(=O)-NH- or -NH-C(=O)-, and X^3 is phenyl optionally substituted with methyl, hydroxy, acetoxy, methoxy, ethoxy, isopropoxy, dimethylamino, hydroxymethyl, methoxymethyl or

carboxy, a compound wherein X^1 is phenyl, X^2 is a bond, $-CH_2-$ or -CH=CH-, and X^3 is imidazolyl, thienyl, pyridyl or tetrazolyl optionally substituted with methyl or phenyl, and a compound wherein X^1 is benzothienyl, isoxazolyl or thienyl optionally substituted with methyl, X^2 is a bond or -S-, and X^3 is phenyl optionally substituted with methoxy or methyl, are excluded, a prodrug, a pharmaceutically acceptable salt, a hydrate thereof.

9. The compound according to claim 8 wherein at least one of X^1 and X^3 is optionally substituted heteroaryl, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

10. The compound according to claim 8 wherein X^1 and X^3 each is independently optionally substituted heteroaryl, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

11. The compound according to claim 8 wherein at least one of X^1 and X^3 is optionally substituted thienyl or optionally substituted benzothienyl, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

12. The compound according to any one of claims 8 to 11 wherein X^2 is a bond, $-CH_2-$, -S-, $-SO_2-$, $-CH_2-O-$, $-O-CH_2-$, $-CH_2-S-$ or $-S-CH_2-$, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

13. The compound according to any one of claims 8 to 12 wherein R^1 is $-CH_2-CH=CH-CH_2-CH_2-CH_2-COOH$, m is 0, and p is 0, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

14. A pharmaceutical composition which comprises a compound according to any one of claims 8 to 13.

15. A pharmaceutical composition having a dual antagonistic activity against PGD_2/TXA_2 receptors which comprises a compound according to any one of claims 8 to 13.

16. The pharmaceutical composition comprising a compound according to claim 14 or 15, which is used for asthma.

17. The pharmaceutical composition comprising a compound according to claim 14 or 15, which is used for nasal blockage.

18. (Added) Use of the compound according to any one of claims 8 to 13 for

manufacturing a pharmaceutical composition for asthma or nasal blockage.

19. (Added) A method for treating asthma or nasal blockage which comprises administering the compound according to any one of claims 8 to 13.